NASDAQ:ALRN - Aileron Therapeutics Stock Price, Forecast & News

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics Inc (NASDAQ:ALRN) posted its earnings results on Thursday, November, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. View Aileron Therapeutics' Earnings History.

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aileron Therapeutics.

3 Wall Street analysts have issued twelve-month price targets for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Aileron Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 663.9% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

Media coverage about ALRN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aileron Therapeutics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Aileron Therapeutics.

Some companies that are related to Aileron Therapeutics include Elite Pharmaceuticals (ELTP), Immunic (IMUX), Infinity Pharmaceuticals (INFI), Axovant Gene Therapies (AXGT), Catalyst Biosciences (CBIO), VERONA PHARMA P/S (VRNA), Cumberland Pharmaceuticals (CPIX), IMMUTEP LTD/S (IMMP), Checkpoint Therapeutics (CKPT), ASLAN PHARMACEU/ADR (ASLN), Eyenovia (EYEN), CTI BioPharma (CTIC), Chembio Diagnostics (CEMI), CNS Pharmaceuticals (CNSP) and Catabasis Pharmaceuticals (CATB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Lexicon Pharmaceuticals (LXRX), Iovance Biotherapeutics (IOVA), Agile Therapeutics (AGRX), Corbus Pharmaceuticals (CRBP), Aurora Cannabis (ACB), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Cronos Group (CRON) and Sorrento Therapeutics (SRNE).

(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALRN stock can currently be purchased for approximately $0.72.

Aileron Therapeutics has a market capitalization of $20.02 million. The company earns $-31,550,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]